Drug Information

Drug (ID: DG00851) and It's Reported Resistant Information

• Name: Tryptophan
• Synonyms: L-tryptophan; tryptophan; 73-22-3; L-Tryptophane; h-Trp-oh; (S)-Tryptophan; Tryptophane; Optimax; trofan; tryptacin; Ardeytropin; (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid; Pacitron; Indole-3-alanine; Kalma; L-beta-3-Indolylalanine; L-Tryptofan; L-Trp; L-(-)-Tryptophan; 3-Indol-3-ylalanine; Tryptan; Lyphan; Tryptophan (VAN); 1-beta-3-Indolylalanine; Tryptophan (H-3); Triptofano [Spanish]; Tryptophanum [Latin]; 1H-Indole-3-alanine; 1beta-3-Indolylalanine; 2-Amino-3-indolylpropanoic acid; L(-)-Tryptophan; triptofano; Tryptophanum; (S)-alpha-Amino-1H-indole-3-propanoic acid; Tryptophane [French]; Tryptophan, L-; (L)-TRYPTOPHAN; (-)-Tryptophan; alpha'-Amino-3-indolepropionic acid; Tryptophan [USAN:INN]; L-alpha-amino-3-indolepropionic acid; L-alpha-Aminoindole-3-propionic acid; Sedanoct; (S)-alpha-Aminoindole-3-propionic acid; 1H-Indole-3-alanine (VAN); EH 121; trp; Alanine, 3-indol-3-yl-; (S)-2-Amino-3-(3-indolyl)propionic acid; CCRIS 617; L-Alanine, 3-(1H-indol-3-yl)-; 1H-Indole-3-alanine, (S)-; alpha-Amino-3-indolepropionic acid, L-; HSDB 4142; (S)-alpha-amino-beta-(3-indolyl)-propionic acid; NCI-C01729; AI3-18478; UNII-8DUH1N11BX; Indole-3-propionic acid, alpha-amino-; 1H-Indole-3-propanoic acid, alpha-amino-, (S)-; Propionic acid, 2-amino-3-indol-3-yl-; CHEBI:16828; Lopac-T-0254; MFCD00064340; 8DUH1N11BX; (S)-alpha-Amino-beta-indolepropionic acid; CHEMBL54976; (S)-2-Amino-3-(1H-indol-3-yl)propanoic acid; DSSTox_CID_1419; DSSTox_RID_76152; DSSTox_GSID_21419; l-b-3-Indolylalanine; D-Trp-OH; CAS-73-22-3; Propionic acid, 2-amino-3-indol-3-yl; L-Tryptophan (9CI); Tryptophan (USP/INN); (S)-a-Amino-b-indolepropionic acid; (S)-a-Aminoindole-3-propionic acid; Alanine, 3-indol-3-yl; EINECS 200-795-6; NSC 13119; (2S)-2-amino-3-(1H-indol-3-yl)propanoate; trytophan; (S)-a-Amino-1H-indole-3-propanoic acid; TRP-01; Trytophan-; 2-amino-3-indol-3-ylpropanoic acid; L-Trytophan; NSC-13119; 1qaw; L-Tryptophan,(S); L-Trp-OH; 2a4m; H-L-Trp-OH; L-Tryptophan (JP17); S(-)-1-alpha-Aminoindole-3-propionic acid; Tryptophan ((-),l,s); Tryptophan (L-Tryptophan); Tryptophan, L- (8CI); bmse000050; bmse000868; bmse001017; Epitope ID:136043; EC 200-795-6; T 0254; SCHEMBL7328; 2-Amino-3-indolylpropanoate; (S)-(-)-2-Amino-3-(3-indolyl)propionic Acid; (S)-1H-Indole-3-alanine; Lopac0_001183; GTPL717; MLS001056750; DivK1c_000457; (s)-a-amino-b-indolepropionate; 151A3008-4CFE-40C9-AC0B-467EF0CB50EA; DTXSID5021419; (S)-a-Aminoindole-3-propionate; BDBM21974; HMS501G19; KBio1_000457; ZINC83315; 3-(1H-indol-3-yl)-L-Alanine; L-a-Amino-3-indolepropionic acid; NINDS_000457; alpha-Aminoindole-3-propionic acid; HMS3263N07; Pharmakon1600-01500600; ACT08662; HY-N0623; L-Tryptophan, Cell Culture Reagent; STR02722; (S)-alpha-Aminoindole-3-propionate; Tox21_201246; Tox21_300359; Tox21_501183; HTS001390; NSC757373; s3987; (s)-alpha-amino-beta-indolepropionate; L-Tryptophan, Vetec(TM), 98.5%; (S)-a-Amino-1H-indole-3-propanoate; AKOS015854052; Indoe-3-propionic acid, alpha-amino-; 2-Chloro-5-(methylsulfonyl)benzoicacid; AM82273; CCG-205257; CS-W020011; DB00150; LP01183; MCULE-8004234494; NSC-757373; SDCCGSBI-0051150.P002; IDI1_000457; NCGC00015994-01; NCGC00094437-01; NCGC00094437-02; NCGC00094437-03; NCGC00094437-04; NCGC00094437-08; NCGC00254424-01; NCGC00258798-01; NCGC00261868-01; (S)-alpha-Amino-1H-indole-3-propanoate; AC-17050; BP-13286; SMR000326686; TS-04426; DB-029986; L-Tryptophan, BioUltra, >=99.5% (NT); A7403; EU-0101183; T0541; (S)-Tryptophan 1H-Indole-3-alanine, (S)-; 73T223; C00078; D00020; L-Tryptophan, reagent grade, >=98% (HPLC); M02943; P16427; AB00373874_05; L-Tryptophan, Vetec(TM) reagent grade, >=98%; (S)-2-amino-3-(1H-Indol-3-yl)-propionic acid; A837752; Q181003; SR-01000075590; 4-(3-METHOXYANILINO)-4-OXOBUT-2-ENOICACID; SR-01000075590-1; F0001-2364; Z1245635763; L-Tryptophan, certified reference material, TraceCERT(R); Tryptophan, European Pharmacopoeia (EP) Reference Standard; UNII-0O72R8RF8A component QIVBCDIJIAJPQS-VIFPVBQESA-N; UNII-N7U7BXP2OI component QIVBCDIJIAJPQS-VIFPVBQESA-N; UNII-X9U7434L7A component QIVBCDIJIAJPQS-VIFPVBQESA-N; L-Tryptophan, United States Pharmacopeia (USP) Reference Standard; 80206-30-0; L-Tryptophan, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 99.0-101.0%; L-Tryptophan, PharmaGrade, Ajinomoto, EP, JP, USP, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture
• Indication:
  In total 1 Indication(s)
  Depression [ICD-11: 6A70]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (1 diseases)
  Melanoma [ICD-11: 2C30]; [1]
• Target: Indoleamine 2,3-dioxygenase 1 (IDO1); I23O1_HUMAN; [1]
• Formula: C11H12N2O2
• IsoSMILES: C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)N
• InChI: 1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m0/s1
• InChIKey: QIVBCDIJIAJPQS-VIFPVBQESA-N
• PubChem CID: 6305
• ChEBI ID: CHEBI:16828
• TTD Drug ID: D05EJG
• VARIDT ID: DR00086
• INTEDE ID: DR0991
• DrugBank ID: DB00150

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Melanoma [ICD-11: 2C30]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Mitogen-activated protein kinase 1 (MAPK1) [1]

• Molecule Alteration: Expression; Up-regulation
• Resistant Disease: Melanoma [ICD-11: 2C30.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• Cell Pathway Regulation: MAPK/RAS signaling pathway; Activation; hsa04010
• In Vivo Model: VillinCreErt2 and VillinCreErt2 APCfl/fl KRASG12D/+ C57BL/6J mouse model; Mus musculus
• Experiment for Molecule Alteration: Amino acid mass spectrometry assay
• Experiment for Drug Resistance: Flow cytometry (SIINFEKL assays); T cell killing assay and clonogenic assay
• Mechanism Description: Sloppiness is defined by ribosomal frameshifting upon tryptophan shortage. MAPK pathway hyperactivation links sloppiness to cancer. Drug-resistant cancer cells remain sloppy and are targeted by T cells.

Key Molecule: Ras-specific guanine nucleotide-releasing factor 2 (RGRF2) [1]

• Molecule Alteration: Expression; Up-regulation
• Resistant Disease: Melanoma [ICD-11: 2C30.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• Cell Pathway Regulation: MAPK/RAS signaling pathway; Activation; hsa04010
• In Vivo Model: VillinCreErt2 and VillinCreErt2 APCfl/fl KRASG12D/+ C57BL/6J mouse model; Mus musculus
• Experiment for Molecule Alteration: Amino acid mass spectrometry assay
• Experiment for Drug Resistance: Flow cytometry (SIINFEKL assays); T cell killing assay and clonogenic assay
• Mechanism Description: Sloppiness is defined by ribosomal frameshifting upon tryptophan shortage. MAPK pathway hyperactivation links sloppiness to cancer. Drug-resistant cancer cells remain sloppy and are targeted by T cells.

References

• Ref 1: Oncogene-dependent sloppiness in mRNA translation .Mol Cell. 2021 Nov 18;81(22):4709-4721.e9. doi: 10.1016/j.molcel.2021.09.002. Epub 2021 Sep 24. 10.1016/j.molcel.2021.09.002